Table 3. Summary of studies.

Study	Trail Design	Participants	Weeks	N	Antipsychotic	Aripiprazole dose(mg/day)	Rate of prolactin level normalization	Prolactin-related symptom recovery
Xu 2006	Placebo-controlled,single-blind	Female	6	60	Risperidone Sulpiride	5	Aripiprazole: 83.3%Placebo: 0%	27/28 patients regained menstruation; 16/16 no longer complained galactorrhea; No change in placebo group.
Shim 2007	Placebo-controlled,double-blind	Either gender	8	54	Haloperidol	15–30	Aripiprazole: 88.5%Placebo: 3.6%	7/11 patients regained menstruation; 1/2 no longer complained galactorrhea; No change in placebo group.
Ji 2008	Placebo-controlled,single-blind	Female	6	130	Risperidone	5	Aripiprazole: 82.0%Placebo: 4.0%	_
Chen 2009	Placebo-controlled,double-blind	Male	8	72	Risperidone	5	Aripiprazole: 67.6%Placebo: 6.5%	_
Kane 2009	Placebo-controlled,double-blind	Either gender	16	322	Risperidone Quetiapine	5–15	Aripiprazole: 19.5%Placebo: 9.1%	_